Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00211
|
|||||
| Drug Name |
Apixaban
|
|||||
| Synonyms |
1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahyd; Apixaban (JAN/USAN/INN); BMS 562247-01; BMS-562247; BMS-562247-01; BMS-562247-01, Apixaban; Eliquis (TN); GG2; Ro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Thrombosis [ICD11:BD71.4, BD72] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C25H25N5O4
|
|||||
| Canonical SMILES |
COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N
|
|||||
| InChI |
InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)
|
|||||
| InChIKey |
QNZCBYKSOIHPEH-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 503612-47-3
|
|||||
| Pharmaceutical Properties | Molecular Weight | 459.5 | Topological Polar Surface Area | 111 | ||
| Heavy Atom Count | 34 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
2.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103535612
,104253239
,109693404
,124757362
,124772059
,125164166
,125433570
,126644898
,126665798
,134339057
,135252374
,135727449
,135727826
,136367462
,136368094
,136920385
,137183704
,139455355
,144115617
,15178464
,152258806
,152343992
,152344098
,160647657
,160874191
,160962913
,160968889
,162011738
,163884621
,164194092
,164777207
,165247616
,170497908
,172912849
,17397366
,174006823
,174549337
,175266926
,175427077
,178103006
,22578033
,26736936
,40272539
,46519072
,51992439
,53812906
,56310620
,57374335
,99375349
,99444299
|
|||||
| ChEBI ID |
CHEBI:72296
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Apixaban was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Characterization of efflux transporters involved in distribution and disposition of apixaban. Drug Metab Dispos. 2013 Apr;41(4):827-35. | |||||
| 3 | Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. Am J Cardiovasc Drugs. 2016 Apr;16(2):119-27. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.